LINC01291: A Potential Drug Target and Biomarker (G102724515)

Target Name: LINC01291

NCBI ID: G102724515

LINC01291

Other Name(s): Long intergenic non-protein coding RNA 1291 | long intergenic non-protein coding RNA 1291

LINC01291: A Potential Drug Target and Biomarker

Non-Protein-Coding RNAs (NP-C RNAs) have emerged as a promising area of research in recent years due to their unique ability to regulate gene expression and play a critical role in various cellular processes. One of the most well-studied NP-C RNAs is LINC01291, which has been shown to be involved in various physiological processes in the cell.

LINC01291 is a long intergenic non-protein-coding RNA (lncRNA) that was identified using RNA sequencing (RNA-seq) data. It has a unique 21-nt read start and a length of 1,291 nts. LINC01291 is located between the genes HSP70 and HSP90, which are involved in the heat shock response.

RNA-seq data has shown that LINC01291 is highly expressed in various tissues and cells, including the brain, heart, liver, and muscle. It has also been shown to be involved in regulating gene expression in various cellular processes, such as cell growth, apoptosis, and inflammation.

One of the most exciting aspects of LINC01291 is its potential as a drug target. The HSP70 and HSP90 proteins are known to play a critical role in the heat shock response, and LINC01291 has been shown to be involved in this response. Therefore, targeting LINC01291 may be a promising way to treat various diseases that are caused by disruptions in the heat shock response, such as cancer, neurodegenerative diseases, and autoimmune diseases.

In addition to its potential as a drug target, LINC01291 has also been shown to be a potential biomarker for various diseases. The heat shock response is a critical pathway that is involved in many cellular processes, including cell growth, apoptosis, and inflammation. Therefore, disrupting the heat shock response has been shown to be a promising strategy for treating various diseases.

LINC01291 has been shown to be involved in the heat shock response by regulating the expression of genes involved in this response. For example, LINC01291 has been shown to be involved in the regulation of the expression of the heat shock protein (HSP) genes Hsp70 and Hsp90. These proteins are known to play a critical role in the heat shock response, and their regulation by LINC01291 may be a promising target for drug developers.

In addition to its potential as a drug target, LINC01291 has also been shown to be a potential biomarker for various diseases. The heat shock response is a critical pathway that is involved in many cellular processes, including cell growth, apoptosis, and inflammation. Therefore, disrupting the heat shock response has been shown to be a promising strategy for treating various diseases.

LINC01291 has been shown to be involved in the regulation of the expression of genes involved in the heat shock response. For example, LINC01291 has been shown to be involved in the regulation of the expression of the heat shock protein (HSP) genes Hsp70 and Hsp90. These proteins are known to play a critical role in the heat shock response, and their regulation by LINC01291 may be a promising target for drug developers.

In conclusion, LINC01291 is a long intergenic non-protein-coding RNA that has been shown to be involved in various physiological processes in the cell. Its unique 21-nt read start and length, as well as its regulation of the heat shock response by the HSP70 and HSP90 proteins, make it an attractive potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of LINC01291 in cellular processes and its potential as a drug

Protein Name: Long Intergenic Non-protein Coding RNA 1291

The "LINC01291 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01291 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets